ObjectiveTo describe and evaluate the pharmacotherapeutic follow-up by a clinical pharmacist in an intensive care unit.MethodsA descriptive and cross-sectional study carried out from August to October 2016. The data were collected through a form, and pharmacotherapeutic follow-up conducted by a clinical pharmacist at the respiratory intensive care unit of a tertiary hospital. The problems recorded in the prescriptions were quantified, classified and evaluated according to severity; the recommendations made by the pharmacist were analyzed considering the impact on pharmacotherapy. The medications involved in the problems were classified according to the Anatomical Therapeutic Chemical Classification System.ResultsForty-six patients were followed up and 192 pharmacotherapy-related problems were registered. The most prevalent problems were missing information on the prescription (33.16%), and those with minor severity (37.5%). Of the recommendations made to optimize pharmacotherapy, 92.7% were accepted, particularly those on inclusion of infusion time (16.67%), and dose appropriateness (13.02%), with greater impact on toxicity (53.6%). Antimicrobials, in general, for systemic use were drug class most often related to problems in pharmacotherapy (53%).ConclusionPharmacotherapeutic follow-up conducted by a pharmacist in a respiratory intensive care unit was able to detect problems in drug therapy and to make clinically relevant recommendations.

Background: In March 2020, COVID-19 was declared a pandemic. In this study, patients were selected through the chest HRCT diagnosis. Laboratory tests such as blood count, fibrinogen, D-dimer, AST, ALT, troponin, LDH, albumin, CRP, electrolytes and ferritin were analyzed. Aims: To monitor the laboratory evolution of COVID-19 in patients during hospitalization. Method: Of 115 patients, 93 were selected and analyzed every three days for 90 days. Data were analyzed using the IBM, SPSS, Statistics for Windows, 23.0 software. Results: 34.4% were female, and 65.6% male; Hct and Hb dropped after the 13th day of hospitalization; leukocyte levels remained up to 15,000, increasing to >20,000 after the 55th day of hospitalization; lymphopenia occurred in 10 to 15% of the patients, with increased eosinophils; platelet levels decreased at the end of hospitalization. Fibrinogen, D-dimer, LDH, CRP and ferritin levels increased throughout the hospitalization period. Urea and creatinine increased slightly from the 30th day onwards. There were no alterations in PTA, troponin, chlorine, potassium and albumin levels, with a decrease throughout the hospitalization period. Conclusion: Knowledge of the behavior of laboratory tests together with the disease evolution give support to the clinical and therapeutic management of COVID-19.

Background In March 2020, COVID-19 was declared a pandemic. In this study, patients were selected through the chest HRCT diagnosis. Laboratory tests such as blood count, fibrinogen, D-dimer, AST, ALT, troponin, LDH, albumin, CRP, electrolytes and ferritin were analyzed. Aims To monitor the laboratory evolution of COVID-19 in patients during hospitalization. Method Of 115 patients, 93 were selected and analyzed every three days for 90 days. Data were analyzed using the IBM, SPSS, Statistics for Windows, 23.0 software. Results 34.4% were female, and 65.6% male; Hct and Hb dropped after the 13th day of hospitalization; leukocyte levels remained up to 15,000, increasing to > 20,000 after the 55th day of hospitalization; lymphopenia occurred in 10 to 15% of the patients, with increased eosinophils; platelet levels decreased at the end of hospitalization. Fibrinogen, D-dimer, LDH, CRP and ferritin levels increased throughout the hospitalization period. Urea and creatinine increased slightly from the 30th day onwards. There were no alterations in PTA, troponin, chlorine, potassium and albumin levels, with a decrease throughout the hospitalization period. Conclusion Knowledge of the behavior of laboratory tests together with the disease evolution give support to the clinical and therapeutic management of COVID-19.

Background: In March 2020, COVID-19 was declared a pandemic. In this study, patients were selected through the chest HRCT diagnosis. Laboratory tests such as blood count, fibrinogen, D-dimer, AST, ALT, troponin, LDH, albumin, CRP, electrolytes and ferritin were analyzed. Aims: To monitor the laboratory evolution of COVID-19 in patients during hospitalization. Method: Of 115 patients, 93 were selected and analyzed every three days for 90 days. Data were analyzed using the IBM, SPSS, Statistics for Windows, 23.0 software. Results: 34.4% were female, and 65.6% male; Hct and Hb dropped after the 13th day of hospitalization; leukocyte levels remained up to 15,000, increasing to >20,000 after the 55th day of hospitalization; lymphopenia occurred in 10 to 15% of the patients, with increased eosinophils; platelet levels decreased at the end of hospitalization. Fibrinogen, D-dimer, LDH, CRP and ferritin levels increased throughout the hospitalization period. Urea and creatinine increased slightly from the 30th day onwards. There were no alterations in PTA, troponin, chlorine, potassium and albumin levels, with a decrease throughout the hospitalization period. Conclusion: Knowledge of the behavior of laboratory tests together with the disease evolution give support to the clinical and therapeutic management of COVID-19.